Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 17/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24787692 | 0.94 | ADORA2B (0.37) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL24787115 | 0.93 | ADORA2B (0.51) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1002670 | 0.84 | ADORA2B (0.49) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL24787527 | 0.82 | ADORA2B (0.54) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL24786783 | 0.81 | ADORA2B (0.43) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1243367 | 0.78 | ADORA2B (0.46) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1002030 | 0.78 | ADORA2B (0.45) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL30073559 | 0.77 | ADORA2B (0.48) | ADORA2BADORA2AADORA1 | |
| SCHEMBL24786743 | 0.77 | ADORA2B (0.48) | ADORA2BADORA2AADORA1 | |
| SCHEMBL1243464 | 0.77 | ADORA2B (0.49) | ADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4341183-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A²B ANTAGONISTS | Adovate, LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11814387-B2 | Cyclic amide-containing pyridyl xanthines as A2B antagonists | ADOVATE, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220402919-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | ADOVATE, LLC | 2022-12-22 | — | — | US | disclosed |
| WO-2022246392-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A 2B ANTAGONISTS | PURNOVATE, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402919-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-11814387-B2 | Cyclic amide-containing pyridyl xanthines as A2B antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.